Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

MYNZEPLI 40 mg/mL solution for injection in a vial {equilateral_black_triangle}

Discontinued
Active Ingredient:
aflibercept
Company:  
ADVANZ Pharma See contact details
ATC code: 
S01LA05
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Audio/Video
{arrow_left}
{arrow_right}
Mynzepli DME Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to diabetic macular oedema (DME)

Mynzepli DME Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to diabetic macular oedema (DME)

Mynzepli WAMD Patient Guide - Your guide to Mynzepli - for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Mynzepli WAMD Patient Guide - Your guide to Mynzepli - for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Mynzepli RVO Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to retinal vein occlusion (RVO)

Mynzepli RVO Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to retinal vein occlusion (RVO)

Mynzepli MCNV Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to myopic choroidal neovascularisation (mCNV)

Mynzepli MCNV Patient Guide - Your guide to Mynzepli - for the treatment of visual impairment due to myopic choroidal neovascularisation (mCNV)

ADVANZ Pharma
Company image
Address
Dashwood House, 69 Old Broad Street, London, EC2M 1QS, UK
Telephone
+44 (0)208 588 9131
Medical Information Direct Line
+44 (0)208 588 9131
Medical Information e-mail
[email protected]
WWW
www.advanzpharma.com
Customer Care direct line
+44 (0)208 588 9273
Medical Information Website
https://medicalinformation.advanzpharma.com/